Company: CRAC
Filing Date: 2025-07-16
Form Type: S-1/A
Source: 0001213900-25-064764
Chunk: 212

Company: Crown Reserve Acquisition Corp. I
Filing Date: 2025-07-16
Form: S-1/A
Chunk 212
---
. Doshi has served as a director since August 2023. On February17, 2025, PowerUp Acquisition Corp. (“New Aspire”), consummated the initial business combination, pursuant to that certain Agreement and Plan of Merger, dated August26, 2024, as amended by an Amendment Agreement dated September5, 2024 and a Second Amendment Agreement dated October9, 2024, by and among the New Aspire, PowerUp Merger Sub II, Inc., a Delaware corporation and wholly owned subsidiary of PowerUp, SRIRAMA Associates, LLC, a Delaware limited liability company, Stephen Quesenberry, in the capacity as the seller representative, 134 and Aspire Biopharma, Inc., a Puerto Rico corporation. New Aspire held a shareholder vote to amend its amended and restated memorandum and articles of association to extend the time that the company had to consummate an initial business combination. Upon closing the agreement, “PowerUp Acquisition Corp.” changed its name to “Aspire Biopharma Holdings, Inc.” Prior to the closing of the business combination, certain New Aspire public shareholders exercised their right to redeem certain of their outstanding shares for cash, resulting in the redemption of 507,631shares of the New Aspire Class A common stock outstanding prior to the business combination for an aggregate payment of $5,882,859. •Aesther Healthcare Acquisition Corp. (n/k/a Ocean Biomedical, Inc. (NASDAQ: OCEA)) — Mr.Patel served as a board advisor. Mr.Peterson has served as a director from June 2021 until the completion of its initial business combination in February 2023. Mr. Peterson now serves as a director of the post -combinationcompany. Mr. Fell served as a director from June 2021 until the completion of its initial business combination in February 2023. On February14, 2023, Aesther Healthcare Acquisition Corp. (“AHAC”) completed the acquisition of Ocean Biomedical Holdings, Inc. pursuant to a definitive agreement, as amended. AHAC exercised two three -monthextension options to complete the transaction. Upon closing the agreement, AHAC changed its name from “Aesther Healthcare Acquisition Corp.” to “Ocean Biomedical, Inc.” Prior to the closing of the business combination, certain AHAC public shareholders exercised their right to redeem certain of their outstanding shares for cash, resulting in the redemption of 10,389,093shares of the company’s Class A common stock